Trade Paratek Pharma - PRTK CFD

Paratek Pharma Company profile

About Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases. The Company's product include NUZYRA (omadacycline) is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens. Its other product includes SEYSARA, which is a oral therapy for the treatment of moderate to severe acne vulgaris.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Paratek Pharmaceuticals Inc revenues increased from $46.9M to $130.2M. Net loss decreased 39% to $59.1M. Revenues reflect Product revenue, net increase from $38.8M to $106.1M, Collaboration and royalty revenue increase from $1.5M to $8.2M, Government contract grant revenue increase from $3.4M to $9.2M. Lower net loss reflects Interest Expense decrease of 14% to $17.4M (expense).

Equity composition

Common Stock $.001 Par, 3/11, 100M auth., 13,467,933 issd. Insiders control 9.22%. IPO: 5/06 .3M shs. @ $6.50 per share by Bear, Stearns & Co. Inc. 02/09, Name changed from Novacea, Inc. 02/09, 5-for-1 reverse stock split. 10/14,1-for-12 reverse stock split.